The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

Merck’s stock fell Thursday morning, despite the company beating profit and sales estimates for the third quarter.

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada , a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling ...

Merck's Q3 sales reached $16.7 billion ... However, the recent performance data has restored confidence, indicating that the drug is experiencing sustained demand growth, with an uptake of ...